At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
toriseldrug
Likely dose
torisel 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study Investigating the Toxicity and Efficacy of Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
In Brief
A Phase 2 clinical trial evaluating torisel for Prostate Cancer. Completed, enrolled 21 participants across 2 sites.
Detailed Summary
This is a single institution, open label, phase II study in androgen-independent prostate cancer patients who are chemotherapy-naïve. Patients will receive Torisel® 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsWyeth is now a wholly owned subsidiary of Pfizer
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJun 2009
Primary CompletionFeb 2013
Study CompletionOct 2013
TodayJul 2026
First PostedJun 11, 2009
Enrollment StartJun 1, 2009
Primary CompletionFeb 1, 2013
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 17.1 years ago
Interventions
toriseldrug
Patients will receive Torisel 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion